Pneumonia, Viral
105
3
3
51
Key Insights
Highlights
Success Rate
78% trial completion
Research Maturity
51 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
13.3%
14 terminated out of 105 trials
78.5%
-8.0% vs benchmark
16%
17 trials in Phase 3/4
16%
8 of 51 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 51 completed trials
Clinical Trials (105)
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study
Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study
A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)
Evaluation of Postmortem Pulmonary Interstitial Fibrosis Severity and EGFR Positivity in Covid-19 Pneumonia
Cromolyn Sodium for Treatment of COVID-19 Pneumonia
Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS
Pediatric Helmet CPAP Pilot Study
AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes
Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.
Diagnostic Accuracy of Pocket-size Lung Ultrasound in Pneumonia Etiology and Complications in Hospitalized Children
Tobacco Use and the Risk of COVID-19 and Adverse Outcomes
Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Antiviral Drugs on the Treatment of SARS-CoV-2
Rehabilitation Treatment of Patients With COVID-19